RNXT Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
RenovoRx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.25 |
| 52 Week High | US$2.35 |
| 52 Week Low | US$0.77 |
| Beta | 1.1 |
| 1 Month Change | -3.10% |
| 3 Month Change | 21.36% |
| 1 Year Change | 21.36% |
| 3 Year Change | -75.44% |
| 5 Year Change | n/a |
| Change since IPO | -82.78% |
Recent News & Updates
Recent updates
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully
Oct 26
Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?
Mar 31Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky
Dec 16RenovoRx reports Q2 results
Aug 15Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?
Aug 04RenovoRx names new finance CFO
Jul 19RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans
Mar 16We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth
Nov 30Shareholder Returns
| RNXT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.3% | -3.6% | -2.4% |
| 1Y | 21.4% | -2.6% | 23.4% |
Return vs Industry: RNXT exceeded the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: RNXT underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| RNXT volatility | |
|---|---|
| RNXT Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RNXT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RNXT's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 10 | Shaun Bagai | renovorx.com |
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors.
RenovoRx, Inc. Fundamentals Summary
| RNXT fundamental statistics | |
|---|---|
| Market cap | US$29.98m |
| Earnings (TTM) | -US$9.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.3x
P/E RatioIs RNXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RNXT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.16m |
| Earnings | -US$9.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RNXT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RenovoRx, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Edward Woo | Ascendiant Capital Markets LLC |
| Jason McCarthy | Maxim Group |